



Hier finden Sie eine Zusammenstellung der Veröffentlichungen von **Mitarbeiterinnen und Mitarbeitern** des BfArM aus dem Jahr 2015

Ahmadzadehfar H, Muckle M, Essler M, Biersack HJ, **von Mallek D** (2015) SPECT/CT: Vorteile und Indikationen der Hybridbildgebung.
Dtsch Med Wochenschr 140(6):434-438

Arloth J, Bogdan R, Weber P, ..., **Steffens M** et al., Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC) (2015) Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders.
Neuron 86(5):1189-1202

Balkow A, Jagow J, **Haas B**, Siegel F, Kilić A, Pfeifer A (2015) A novel crosstalk between Alk7 and cGMP signaling differentially regulates brown adipocyte function.
Mol Metab 4(8):576-583

Beinlich P, Müller-Berghaus J, **Sudhop T**, Vieths S, **Broich K** (2015) Zusammenspiel zwischen Zulassung und Nutzenbewertung von Arzneimitteln.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58(3):227-231

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, **Stingl JC**, Tsai SJ, Kubo M, Klein TE, Weinshilboum R (2015) The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
Transl Psychiatry 5:e553

Blumberg A (2015) Ambroxol/Bromhexin - Risiko für allergische Reaktionen und schwere Hautreaktionen - europäisches Bewertungsverfahren.
Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 1:3-7

Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, **Broich K**, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo LA, Nicolas F, Pani L, Robinson L, Siviero P, van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L (2015) Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.
Alzheimers Dement 11(4):455-461



Brockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, Fuchs T, Jakob T, Lange L, Pfützner W, Mockenhaupt M, Ott H, Pfaar O, Ring J, **Sachs B**, Sitter H, Trautmann A, Treudler R, Wedi B, Worm M, Wurpts G, Zuberbier T, Merk HF (2015) Leitlinie Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel.
Allergo J 24(3):44-57

Broich K, Greiner C, Paeschke N, Huber M (2015) Antidepressiva in der Schwangerschaft - Eine Betrachtung aus regulatorischer Sicht.
Psychopharmakotherapie 22(6):268-277

Casper M, **Mengel M**, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grünhage F, Lammert F and the INCA trial group (2015) The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial.
Trials 16(1):83

Coenen M, **Hinze AV, Mengel M**, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, **Stingl JC**, Holdenrieder S, Müller M, Hartmann G, Coch C (2015) Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon-based therapies.
BMC Pharmacol Toxicol 16(1):25

Cremer-Schaeffer P, Broich K (2015) Betäubungsmittelrecht und Palliativversorgung. Behindern die betäubungsmittelrechtlichen Rahmenbedingungen die Patientenversorgung in der Palliativmedizin?
Gesundh ökon Qual manag 20(05):216-220

Cremer-Schaeffer P, Broich K (2015) Betäubungsmittelversorgung: Bürokratiekostenabbau durch Einführung des elektronischen Abgabebelegverfahrens.
Gesundh ökon Qual manag 20(05):221-225

Dexel F, Mehrpuyan A (2015) Datenschutz in der Pharmakovigilanz aus Sicht der Behörden: Was geschieht mit den Patienteninitialen?
Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 3:24-28

Diesinger C, Heymans L (2015) Osteonekrosen des Kiefers und Osteonekrosen des äußeren Gehörgangs unter der Therapie mit Bisphosphonaten oder Denosumab - neue risikominimierende Maßnahmen.
Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 4:3-9



Fabbri C, Crisafulli C, Gurwitz D, **Stingl JC**, Calati R, Albani D, Forloni G, Calabro M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Girolamo GD, Serretti A (2015) Neuronal cell adhesion genes and antidepressant response in three independent samples.

Pharmacogenomics J advance online publication 7 April 2015; doi:10.1038/tpj.2015.15

Frisch CM, Zimmermann K, **Zilleßen P**, Pfeifer A, Racké K, **Mayer P** (2015) Non-small cell lung cancer cell survival crucially depends on functional insulin receptors.

Endocr Relat Cancer 22(4):609-621

Frötschl R (2015) Experiences with the in vivo and in vitro comet assay in regulatory testing.

Mutagenesis 30(1):51-57

Frötschl R, Müller L (2015) ICH M7 - Leitlinie zur Bewertung und Kontrolle von DNA-reaktiven (mutagenen) Verunreinigungen in Arzneimitteln zur Begrenzung des karzinogenen Risikos.

Pharm Ind 77(9):1320-1325

García Arieta A, Gordon J, **Potthast H** (2015) On the Biopharmaceutics Classification System Biowaiver of Ibuprofen.

J Pharm Sci 104(8):2429-2432

Gollapudi B, Lynch A, Heflich R, Dertinger S, Dobrovolsky V, **Frötschl R**, Horibata K, Kenyon M, Kimoto T, Lovell D, Stankowski JL, White P, Witt K, Tanir J (2015) The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup.

Mutat Res Genet Toxicol Environ Mutagen 783:23-25

Guérard M, Baum M, Bitsch A, Eisenbrand G, Elhajouji A, Epe B, Habermeyer M, Kaina B, Martus H, Pfuhler S, Schmitz C, Sutter A, Thomas A, Ziemann C, **Frötschl R** (2015) Assessment of mechanism driving non-linear dose-response relationships in genotoxicity testing.

Mutat Res Rev Mutat Res 763:181-201

Gwaza L, Gordon J, **Potthast H**, Welink J, Leufkens H, Stahl M, García-Arieta A (2015) Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons.

Eur J Clin Pharmacol 71(9):1083-1089



Haas B, von Mallek D, Eckstein N (2015) Sensibilisierung von Glioblastomzellen gegenüber Temozolomid.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 1:24-28

Haas M, Mantua V, **Haberkamp M**, Pani L, Isaac M, Butlen-Ducuing F, Vamvakas S, **Broich K** (2015) The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.

Nat Rev Drug Discov 14(4):221-222

Haas M, Vlcek V, Balabanov P, Salmonson T, Bakchine S, Markey G, **Weise M, Schlosser-Weber G, Brohmann H**, Yerro CP, Mendizabal MR, Stoyanova- Beninska V, Hillege HL (2015) European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.

Neuromuscul Disord 25(1):5-13

Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, Brettschneider C, König HH, Werle J, Weyerer S, Luppä M, Riedel-Heller SG, Fuchs A, Pentzek M, Weeg D, Bickel H, **Broich K**, Jessen F, Maier W, Scherer M (2015) Risk of dementia in elderly patients with the use of proton pump inhibitors.

Eur Arch Psychiatry Clin Neurosci 265(5):419-428

Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, **Broich K**, Nistico R, Aisen PS, Lista S (2015) Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

Expert Rev Neurother 15(1):83-105

Hannig J, **Siekmeier R** (2015) Field Safety Notes in Product Problems of Medical Devices for Use in Pulmonology.

Adv Exp Med Biol 861:31-41

Hasheminasab SM, Tzvetkov MV, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, **Steffens M, Scholl C, Hichert V**, Seufferlein T, Brockmöller J, **Stingl JC** (2015) High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.

Pharmacogenomics 16(14):1605-1619

Helms HJ, **Benda N**, Friede T (2015) Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

J Biopharm Stat 25(5):939-957



Helms HJ, **Benda N**, **Zinserling J**, Kneib T, Friede T (2015) Spline-based procedures for dose-finding studies with active control.

Stat Med 34(2):232-248

Hichert V, **Steffens M**, Paul T, **Scholl C**, Parmar S, Rüdiger S, Schumann C, Seufferlein T, **Stingl JC** (2015) Gene regulatory biomarker identification for skin toxicities induced by EGFR inhibitor treatment.

Int J Clin Pharmacol Ther 53(12):1056-1058

Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar T, Scott S, **Stingl JC**, Klein TE, Caudle K, Gaedigk A (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Clin Pharmacol Ther 98(2):127-134

Holtzman D, Nikolich K, Pangalos M, **Broich K**, Ip N, Koo E, Koroshetz W, Masliah E, Mucke L, Nicotera P, Schnaars M, Spillantini M (2015) Neurodegenerative Diseases: What Is to Be Done? In: Nikolich K, Hyman SE (Hrsg) *Translational Neuroscience: Toward New Therapies*. MIT Press, 93-113

Huber M, **Schlosser-Weber G**, **Paeschke N**, **Broich K** (2015) Antipsychotika in der Schwangerschaft - Eine Betrachtung aus regulatorischer Sicht.

Psychopharmakotherapie 22(6):278-285

Juraeva D, Treutlein J, Scholz H, ..., **Steffens M** et al. (2015) XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in *Drosophila* and humans.

Neuropsychopharmacology 40(2):361-371

Kaumanns K, **Kayser C**, **Paeschke N**, **von Mallek D**, **Stingl JC**, Köberle U, Aly AF, Bräutigam K, Stammschulte T, Gundert-Remy U (2015) Medikationsfehler im Fokus der Forschung und Pharmakovigilanz.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:27-35

Keksel C, Zumpf N, Bohrer B, **Hass MD**, **Haas B**, **Eckstein N** (2015) GMP & GCP: Qualitätsmanagement-Systeme in der Pharmazeutischen Industrie.

UniDAZ 2:27-33



Klenk J, Kerse N, Rapp K, Nikolaus T, Becker C, Rothenbacher D, Peter R, Denking MD, the ActiFE Study Group (**Stingl JC**) (2015) Physical Activity and Different Concepts of Fall Risk Estimation in Older People - Results of the ActiFE-Ulm Study.

PLoS One 10(6):e0129098

Knöss W (2015) Contributions and visions of the Committee on Herbal Medicinal Products (HMPC). 63rd International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA 2015), 2015, Budapest, Hungary.

Planta Med 81(16):RAW_01

Knöss W (2015) European regulatory framework for herbal medicinal products - Challenges for Traditional Medicines. 15th International Conference on the Science of Botanicals, Oxford, Mississippi USA.

Planta Med 81, OA28:395

Knöss W (2015) Harmonisierung in der Pflanzenheilkunde: Europäische Standards für pflanzliche Arzneimittel.

Österreichische Apotheker-Zeitung 69(6):25-27

Knöss W (2015) Harmonization of regulatory requirements in Europe to ensure quality, safety and efficacy of herbal medicinal products. In: Mukherjee PK (Hrsg) Evidence-Based Validation of Herbal Medicine. Elsevier Science, 201-216

Knöss W, Chinou I (2015) Traditional herbal medicines in the European Union: Implementing standardization and regulation. In: The Art and Science of Traditional Medicine Part 3: The Global Impact of Traditional Medicine.

Science 350(6262):871, S59-S60; doi: 10.1126/science.350.6282.871-c

Krappweis J, Schwabe D (2015) Erythropoietin - zusätzliches Risiko einer Retinopathie bei Frühgeborenen nicht auszuschließen.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 3:3-6

Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N (2015) Choosing appropriate estimands in clinical trials.

Ther Innov Regul Sci 49(4):584-592

Lilienthal N (2015) Der vergessene Rest - Totvolumina bei Kurzinfusionen.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:3-9



Lipke U (2015) Grundlagen der Validierung von Prüfverfahren für genotoxische Verunreinigungen.

Pharm Ind 77(6):910-919

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, **Broich K**, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H (2015) Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

J Alzheimers Dis 48(Suppl 1):S171-191

Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, Baron-Cohen S, **Broich K**, Bolte S, Bourgeron T, Charman T, Collier D, de Andres-Trelles F, Durston S, Ecker C, Elferink A, **Haberkamp M**, Hemmings R, Johnson MH, Jones EJH, Khwaja OS, Lenton S, Mason L, Mantua V, Meyer-Lindenberg A et al. (2016) Identification and validation of biomarkers for autism spectrum disorders.

Nat Rev Drug Discov 15(1):70-73. Published online 31 December 2015. doi:10.1038/nrd.2015.7

Lundt A, Wormuth C, Siwek ME, Müller R, Ehniger D, Henseler C, Broich K, Papazoglou A, Weiergräber M (2015) EEG Radiotelemetry in Small Laboratory Rodents: A Powerful State-of-the Art Approach in Neuropsychiatric, Neurodegenerative, and Epilepsy Research.

Neural Plast Epub ahead of print 24 Dec 2015

MacGregor J, **Frötschl R**, White P, Crump K, Eastmond D, Fukushima S, Guérard M, Hayashi M, Soeteman-Hernández L, Kasamatsu T, Levy D, Morita T, Müller L, Schoeny R, Schuler M, Thybaud V, Johnson G (2015) IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure-response relationships and points of departure (PoDs).

Mutat Res Genet Toxicol Environ Mutagen 783:55-65

MacGregor J, **Frötschl R**, White P, Crump K, Eastmond D, Fukushima S, Guérard M, Hayashi M, Soeteman-Hernández L, Johnson G, Kasamatsu T, Levy D, Morita T, Müller L, Schoeny R, Schuler M, Thybaud V (2015) IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk.

Mutat Res Genet Toxicol Environ Mutagen 783:66-78



Maier R, Moser G, Chen GB, Ripke S, Cross-Disorder Working Group of the Psychiatric Genomics Consortium, ..., **Steffens M** et al. (2015) Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder.

Am J Hum Genet 96(2):283-294

Martus HJ, Hayashi M, Honma M, **Kasper P**, Gollapudi B, Mueller L, Schoeny R, Uno Y, Kirkland DJ (2015) Summary of major conclusions from the 6th International Workshop on Genotoxicity Testing (IWGT), Foz do Iguacu, Brazil.

Mutat Res Genet Toxicol Environ Mutagen 783:1-5

Matz S, Gröger T (2015) Antibiotikaresistenz - wenn Antibiotika nicht mehr wirken.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 3:12-23

Meier T (2015) Modifikation der Kontraindikationen und Warnhinweise bei Metformin.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:10-14

Nagel G, Herbolsheimer F, Riepe M, Nikolaus T, Denking MD, Peter R, Weinmayr G, Rothenbacher D, Koenig W, Ludolph AC, von Arnim CA, ActiFE Study Group (**Stingl JC** et al.) (2015) Serum Vitamin D Concentrations and Cognitive Function in a Population-Based Study among Older Adults in South Germany.

J Alzheimers Dis 45(4):1119-1126

Nopitsch-Mai C, Winterscheid S (2015) A guide to the EU variation procedure from a quality viewpoint.

Regulatory Rapporteur 12(4):4-7

Paesler K, Xie K, Hettich MM, **Siwek ME**, Ryan DP, Schröder S, **Papazoglou A, Broich K, Müller R, Trog A, Garthe A, Kempermann G, Weiergräber M, Ehninger D** (2015) Limited effects of an eIF2a S51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease.

Neural Plast 2015:825157

Peyrot WJ, Lee SH, Milaneschi Y, Abdellaoui A, Byrne EM, ..., **Steffens M** et al., Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium Corporate Collaborator (2015) The association between lower educational attainment and depression owing to shared genetic effects? Results in ~ 25 000 subjects.

Mol Psychiatry 20(6):735-743



Pfeifer V, **Lilienthal N, Eckstein N** (2015) Arzneimittelskandale und -unfälle Teil II - MEDIATOR®, UKRAIN® & Co.
UniDAZ 1:26-30

Pfeifer V, Metzger A, **Norta M, Enzmann H, Eckstein N** (2015) Ähnlich, gleich oder klinisch überlegen? Das Similarity Assessment bei Orphan Drugs.
Dtsch Apoth Ztg 38:66-72

Pfeifer V, Metzger A, **Norta M, Enzmann H, Eckstein N** (2015) Hilfe bei seltenen Krankheiten.
Dtsch Apoth Ztg 38:58-64

Potthast H, Garcia-Arieta A - Biowaiving based on the BCS - The EMA Approach. Chapter in "Biopharmaceutics Classification System (BCS): Development, Implementation and Growth" Mehta M (Hrsg), submitted January 2015

Prinz N, **Stingl JC**, Dapp A, Denkinger MD, Fasching P, Jehle PM, Merger S, Mühldorfer S, Pieper U, Schuler A, Zeyfang A, Holl RW (2015) High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: A multicenter cohort study on 215,932 patients from the German/ Austrian diabetes registry.
Diabetes Res Clin Pract Epub ahead of print 30 Oct 2015

Probst-Schendzielorz K, **Scholl C**, Efimkina O, Ersfeld E, Viviani R, Serretti A, Fabbri C, Gurwitz D, Lucae S, Ising M, Paul AM, Lehmann M-L, **Steffens M**, Crisafulli C, Calabro M, Holsboer F, **Stingl JC** (2015) CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.
Pharmacogenomics 16(7):689-701

Probst-Schendzielorz K, Viviani R, **Stingl JC** (2015) Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
Expert Opin Drug Metab Toxicol 11(8):1219-1232

Rautanen A, Mills TC, Gordon AC, Hutton P, **Steffens M** et al. (2015) Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.
Lancet Respir Med 3(1):53-60

Sachs B, Fischer-Barth W (2015) Überempfindlichkeitsreaktionen auf verschreibungspflichtige Arzneimittel in der ambulanten Verordnung.
Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 4:16-27



Sachs B, Fischer-Barth W, Merk HF (2015) Reporting rates for severe hypersensitivity reactions associated with prescription-only drugs in outpatient treatment in Germany. *Pharmacoepidemiol Drug Saf* 24(10):1076-1084

Sauerbruch T, **Mengel M**, Dollinger M, Zipprich A, Rössle M, Panther E, Wiest R, Caca K, Hoffmeister A, Lutz H, Schoo R, Lorenzen H, Trebicka J, Appenrodt B, Schepke M, Fimmers R, for the German Study Group for Prophylaxis of Variceal Rebleeding (2015) Prevention of Rebleeding from Esophageal Varices in Patients with Cirrhosis Receiving Small-diameter Stents vs Hemodynamically Controlled Medical Therapy. *Gastroenterology* 149:660-668

Schiller K, Reich E, Heilmann J, **Manns D**, Franz G (2015) Development of an HPTLC-method for identification of *Scrophulariae radix* (Xuanshen) and quantification of the two main iridoids, harpagide and harpagoside. *Planta Med* 81(16):PW_213

Schmidt K, Völkel H, Sudhop T, Broich K (2015) Rechtlicher Rahmen und Ablauf von Risikobewertungsverfahren des BfArM. *Arzneimittel & Recht* 5:195-201

Schmidt T, **Brodesser A**, Schnitzler N, **Grüger T, Brandenburg K, Zinserling J, Zündorf J** (2015) CD66b Overexpression and Loss of C5a Receptors as Surface Markers for *Staphylococcus aureus*-Induced Neutrophil Dysfunction. *PLoS One* 10(7):e0132703. doi:10.1371/journal.pone

Schneider CK, **Weise M** (2015) Regulatorische Aspekte zu Biosimiliars: Mythen und Fakten. *Z Rheumatol* 74(8):695-700

Schriever J, Bühlen M, Huber M, Paeschke N (2015) Migränetherapie in der Schwangerschaft - Aktueller Kenntnisstand. *Psychopharmakotherapie* 22(6):305-312

Schulte A, Broich K, Schwerdtfeger W (2015) Arzneimittelversorgung. In: Thielscher C (Hrsg) *Medizinökonomie 1: Das System der medizinischen Versorgung*. Springer-Gabler-Verlag Wiesbaden, 2., aktualisierte und erw. Auflage, S. 373-404 (ISBN: 978-3-658-01965-5)

Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Ising M, ..., **Steffens M** et al. (2015) Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. *Behav Genet* Epub ahead of print 21 Sept 2015



Siwek ME, Müller R, Henseler C, Trog A, Lundt A, Wormuth C, Broich K, Ehninger D, Weiergräber M, Papazoglou A (2015) Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.
Neural Plast 2015:781731

Speit G, Kojima H, Burlinson B, Collins AR, **Kasper P**, Plappert-Helbig U, Uno Y, Vasquez M, Beevers C, De Boeck M, Escobar PA, Kitamoto S, Pant K, Pfuhler S, Tanaka J, Levy DD (2015) Critical issues with the in vivo comet assay: A report of the comet assay working group in the 6th International Workshop on Genotoxicity Testing (IWGT).
Mutat Res Genet Toxicol Environ Mutagen 783:6-12

Spicher K, Brendler-Schwaab S, Schlösser C, Catarinolo M, Fütterer S, Langguth P, Enzmann H (2015) Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.
Regul Toxicol Pharmacol 73(1):65-72

Stingl JC, Kaumanns K, von Mallek D (2015) Erfassung und Analyse von Medikationsfehlern in drei zentralen Notaufnahmen Deutschlands - eine prospektive observationelle Studie.
Arzneiverordnung in der Praxis 42(3):111-115

Stingl JC, Rothhauwe J (2015) Codein: Neue Anwendungsbeschränkungen bei Kindern und Jugendlichen.
Dtsch Med Wochenschr 140(14):1093-1095

Stingl JC, Viviani R (2015) Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
J Intern Med 277(2):167-177

Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R (2015) Where Failure Is Not an Option - Personalized Medicine in Astronauts.
PLoS One 10(10):e0140764

Stöhr M, Pfeifer V, Franken C, **Eckstein N** (2015) Evidenzbasierte Medizin: Historie, Möglichkeiten und Grenzen.
Onkologische Pharmazie 3:83-87

Strada L, Schulte B, Schmidt CS, Verthein U, **Cremer-Schaeffer P, Krückeberg S, Reimer J** (2015) Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.
BMC Infect Dis 15(1):563



Weiergräber M (2015) A scientific assessment of $\text{Ca}_v2.3$ voltage-gated Ca^{2+} channels in rodent sleep architecture.

Sleep 38(3):501-502

Weiergräber M (2015) $\text{Ca}_v2.3$ R-type Ca^{2+} channels in mouse sleep architecture - an update.

Somnologie 19(1):61-62

Weiergräber M, Papazoglou A (2015) $\text{Ca}_v2.3$ R-type Ca^{2+} channels in anticonvulsive treatment.

Epilepsia 56(7):1180-1181

Weiergräber M, Papazoglou A (2015) EEG-Biomarker in der Früherkennung und Verlaufskontrolle der Alzheimer-Demenz.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 4:37-41

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH, EU-PACT Group (**Stingl JC** et al.) (2015) Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.

Thromb Res 136(1):94-100